The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Cancer treatment in the past few years has been transformed by a new kind of therapy that targets the immune system instead of the cancer itself to reinvigorate antitumor immunity with astonishing results. However, primary and acquired resistance to this type of treatment, namely immune checkpoint blockade (ICB), continue to counter treatment efficacy. In many cases, resistance has been attributed to defective or chronically enhanced interferon signaling and/or upregulation of alternative immune checkpoints, including T-cell immunoglobulin mucin-3 (Tim-3) and its ligand galactin-9 (Gal-9). In this article, we briefly describe the current knowledge of common checkpoint resistance mechanisms, focusing on the Tim-3/Gal-9 pathway as an alternative checkpoint that holds great promise as another target for ICB.

Original languageEnglish (US)
Pages (from-to)1058-1064
Number of pages7
JournalScience China Life Sciences
Volume60
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Mucin-3
Galectins
T-cells
mucins
immunotherapy
immunity
Immunotherapy
immunoglobulins
ligand
Immunoglobulins
Immunity
cancer
T-lymphocytes
Ligands
T-Lymphocytes
neoplasms
Oncology
Immune system
immune system
interferons

Keywords

  • Tim-3
  • cancer
  • galectin-9
  • immune checkpoints
  • immunotherapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)
  • Agricultural and Biological Sciences(all)

Cite this

@article{159caefa5790438eb2a0f866a045c7a8,
title = "The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy",
abstract = "Cancer treatment in the past few years has been transformed by a new kind of therapy that targets the immune system instead of the cancer itself to reinvigorate antitumor immunity with astonishing results. However, primary and acquired resistance to this type of treatment, namely immune checkpoint blockade (ICB), continue to counter treatment efficacy. In many cases, resistance has been attributed to defective or chronically enhanced interferon signaling and/or upregulation of alternative immune checkpoints, including T-cell immunoglobulin mucin-3 (Tim-3) and its ligand galactin-9 (Gal-9). In this article, we briefly describe the current knowledge of common checkpoint resistance mechanisms, focusing on the Tim-3/Gal-9 pathway as an alternative checkpoint that holds great promise as another target for ICB.",
keywords = "Tim-3, cancer, galectin-9, immune checkpoints, immunotherapy",
author = "Riyao Yang and Hung, {Mien Chie}",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s11427-017-9176-7",
language = "English (US)",
volume = "60",
pages = "1058--1064",
journal = "Science China Life Sciences",
issn = "1674-7305",
publisher = "Science in China Press",
number = "10",

}

TY - JOUR

T1 - The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy

AU - Yang, Riyao

AU - Hung, Mien Chie

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Cancer treatment in the past few years has been transformed by a new kind of therapy that targets the immune system instead of the cancer itself to reinvigorate antitumor immunity with astonishing results. However, primary and acquired resistance to this type of treatment, namely immune checkpoint blockade (ICB), continue to counter treatment efficacy. In many cases, resistance has been attributed to defective or chronically enhanced interferon signaling and/or upregulation of alternative immune checkpoints, including T-cell immunoglobulin mucin-3 (Tim-3) and its ligand galactin-9 (Gal-9). In this article, we briefly describe the current knowledge of common checkpoint resistance mechanisms, focusing on the Tim-3/Gal-9 pathway as an alternative checkpoint that holds great promise as another target for ICB.

AB - Cancer treatment in the past few years has been transformed by a new kind of therapy that targets the immune system instead of the cancer itself to reinvigorate antitumor immunity with astonishing results. However, primary and acquired resistance to this type of treatment, namely immune checkpoint blockade (ICB), continue to counter treatment efficacy. In many cases, resistance has been attributed to defective or chronically enhanced interferon signaling and/or upregulation of alternative immune checkpoints, including T-cell immunoglobulin mucin-3 (Tim-3) and its ligand galactin-9 (Gal-9). In this article, we briefly describe the current knowledge of common checkpoint resistance mechanisms, focusing on the Tim-3/Gal-9 pathway as an alternative checkpoint that holds great promise as another target for ICB.

KW - Tim-3

KW - cancer

KW - galectin-9

KW - immune checkpoints

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85031414359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031414359&partnerID=8YFLogxK

U2 - 10.1007/s11427-017-9176-7

DO - 10.1007/s11427-017-9176-7

M3 - Review article

C2 - 29027155

AN - SCOPUS:85031414359

VL - 60

SP - 1058

EP - 1064

JO - Science China Life Sciences

JF - Science China Life Sciences

SN - 1674-7305

IS - 10

ER -